Symbols / RLAY Stock $13.22 +2.24% Relay Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
RLAY (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Sanjiv K. Patel M.A., M.B.A., M.D., M…
Exch · Country NGM · United States
Market Cap 2.53B
Enterprise Value 1.92B
Income -272.70M
Sales 10.68M
FCF (ttm) -121.18M
Book/sh 3.26
Cash/sh 3.35
Employees 193
Insider 10d —
IPO Jul 16, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -7.67
PEG —
P/S 237.24
P/B 4.05
P/C —
EV/EBITDA -6.55
EV/Sales 180.06
Quick Ratio 21.58
Current Ratio 22.13
Debt/Eq 4.92
LT Debt/Eq —
EPS (ttm) -1.56
EPS next Y -1.72
EPS Growth —
Revenue Growth -60.90%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-05
Earnings (prior) 2026-05-05
ROA -24.72%
ROE -40.01%
ROIC —
Gross Margin 0.00%
Oper. Margin -26.20%
Profit Margin 0.00%
Shs Outstand 191.59M
Shs Float 115.91M
Insider Own 1.58%
Instit Own 92.08%
Short Float 17.09%
Short Ratio 7.58
Short Interest 27.41M
52W High 17.32
vs 52W High -23.67%
52W Low 2.67
vs 52W Low 395.13%
Beta 1.75
Impl. Vol. 3.89%
Rel Volume 0.78
Avg Volume 2.95M
Volume 2.31M
Target (mean) $21.00
Tgt Median $21.00
Tgt Low $18.00
Tgt High $25.00
# Analysts 12
Recom Strong_buy
Prev Close $12.93
Price $13.22
Change 2.24%
About

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$21.00
Mean price target
2. Current target
$13.22
Latest analyst target
3. DCF / Fair value
$-11.39
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$13.22
Low
$18.00
High
$25.00
Mean
$21.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-29 main HC Wainwright & Co. Buy → Buy $25
2026-04-28 main Goldman Sachs Buy → Buy $22
2026-04-28 main Citizens Market Outperform → Market Outperform $19
2026-04-28 main Wells Fargo Overweight → Overweight $21
2026-04-28 main Oppenheimer Outperform → Outperform $18
2026-04-14 init Jones Trading — → Hold $18
2026-04-08 main Barclays Overweight → Overweight $21
2026-03-23 main HC Wainwright & Co. Buy → Buy $19
2026-03-17 main Citizens Market Outperform → Market Outperform $17
2026-03-17 main Wells Fargo Overweight → Overweight $17
2026-03-13 main Guggenheim Buy → Buy $22
2026-02-27 main Wells Fargo Overweight → Overweight $15
2026-01-26 up Oppenheimer Perform → Outperform $14
2025-12-12 up Wells Fargo Equal-Weight → Overweight $13
2025-11-07 main Wells Fargo Equal-Weight → Equal-Weight $6
2025-08-26 main HC Wainwright & Co. Buy → Buy $14
2025-08-08 main Raymond James Strong Buy → Strong Buy $19
2025-05-07 main Guggenheim Buy → Buy $10
2025-04-17 init Wells Fargo — → Equal-Weight $4
2025-03-07 reit HC Wainwright & Co. Buy → Buy $16
News
RSS: Latest RLAY news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-28 BERGSTROM DONALD A. Officer — 1,490 $14.79 $22,037
2026-04-28 CATINAZZO THOMAS J Chief Financial Officer — 972 $14.79 $14,376
2026-04-28 RAHMER PETER J Officer — 753 $14.79 $11,137
2026-04-09 CATINAZZO THOMAS J Chief Financial Officer — 1,800 $5.22 $9,396
2026-04-09 CATINAZZO THOMAS J Chief Financial Officer — 19,517 $13.01 $257,498
2026-03-09 CATINAZZO THOMAS J Chief Financial Officer — 17,717 $10.06 $178,233
2026-01-28 BERGSTROM DONALD A. Officer — 21,581 $7.62 $166,677
2026-01-28 CATINAZZO THOMAS J Chief Financial Officer — 15,515 $7.62 $119,631
2026-01-28 RAHMER PETER J Officer — 13,038 $7.62 $100,473
2026-01-06 PATEL SANJIV NARATANBHAI Chief Executive Officer — 43,168 $7.82 $337,574
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
15.36
+53.44%
10.01
-60.83%
25.55
+1749.82%
1.38
Operating Revenue
15.36
+53.44%
10.01
-60.83%
25.55
+1749.82%
1.38
Operating Expense
318.09
-19.61%
395.68
-2.29%
404.97
+29.66%
312.33
Research And Development
261.38
-18.08%
319.09
-3.31%
330.02
+33.96%
246.35
Selling General And Administration
56.71
-25.96%
76.59
+2.19%
74.95
+13.60%
65.98
General And Administrative Expense
56.71
-25.96%
76.59
+2.19%
74.95
+13.60%
65.98
Other Gand A
56.71
-25.96%
76.59
+2.19%
74.95
+13.60%
65.98
Total Expenses
318.09
-19.61%
395.68
-2.29%
404.97
+29.66%
312.33
Operating Income
-302.74
+21.50%
-385.67
-1.65%
-379.42
-22.02%
-310.95
Total Operating Income As Reported
-302.74
+18.72%
-372.47
+0.14%
-373.00
-24.63%
-299.27
EBITDA
-299.18
+21.31%
-380.21
-1.62%
-374.15
-21.94%
-306.82
Normalized EBITDA
-299.18
+23.95%
-393.42
-3.37%
-380.57
-19.49%
-318.50
Reconciled Depreciation
3.56
-34.90%
5.46
+3.70%
5.27
+27.58%
4.13
EBIT
-302.74
+21.50%
-385.67
-1.65%
-379.42
-22.02%
-310.95
Total Unusual Items
0.00
-100.00%
13.21
+105.64%
6.42
-45.00%
11.68
Total Unusual Items Excluding Goodwill
0.00
-100.00%
13.21
+105.64%
6.42
-45.00%
11.68
Special Income Charges
0.00
-100.00%
13.21
+105.64%
6.42
-45.00%
11.68
Other Special Charges
—
—
—
—
Restructuring And Mergern Acquisition
0.00
+100.00%
-13.21
-105.64%
-6.42
+45.00%
-11.68
Net Income
-276.48
+18.13%
-337.71
+1.25%
-341.97
-17.72%
-290.51
Pretax Income
-276.48
+18.13%
-337.71
+1.25%
-341.97
-17.72%
-290.51
Net Non Operating Interest Income Expense
27.04
-22.19%
34.75
+11.92%
31.05
+253.35%
8.79
Net Interest Income
27.04
-22.19%
34.75
+11.92%
31.05
+253.35%
8.79
Interest Income Non Operating
27.04
-22.19%
34.75
+11.92%
31.05
+253.35%
8.79
Interest Income
27.04
-22.19%
34.75
+11.92%
31.05
+253.35%
8.79
Other Income Expense
-0.78
-105.87%
13.22
+106.43%
6.40
-45.06%
11.66
Other Non Operating Income Expenses
-0.78
-5642.86%
0.01
+177.78%
-0.02
+10.00%
-0.02
Gain On Sale Of Security
—
—
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-276.48
+18.13%
-337.71
+1.25%
-341.97
-17.72%
-290.51
Net Income From Continuing Operation Net Minority Interest
-276.48
+18.13%
-337.71
+1.25%
-341.97
-17.72%
-290.51
Net Income From Continuing And Discontinued Operation
-276.48
+18.13%
-337.71
+1.25%
-341.97
-17.72%
-290.51
Net Income Continuous Operations
-276.48
+18.13%
-337.71
+1.25%
-341.97
-17.72%
-290.51
Normalized Income
-276.48
+21.21%
-350.91
-0.72%
-348.39
-15.29%
-302.19
Net Income Common Stockholders
-276.48
+18.13%
-337.71
+1.25%
-341.97
-17.72%
-290.51
Diluted EPS
—
-2.36
+15.41%
-2.79
-7.72%
-2.59
Basic EPS
—
-2.36
+15.41%
-2.79
-7.72%
-2.59
Basic Average Shares
—
142.87
+16.55%
122.58
+9.22%
112.23
Diluted Average Shares
—
142.87
+16.55%
122.58
+9.22%
112.23
Diluted NI Availto Com Stockholders
-276.48
+18.13%
-337.71
+1.25%
-341.97
-17.72%
-290.51
Line Item Trend 2023-12-31
Total Assets
843.98
Current Assets
770.10
Cash Cash Equivalents And Short Term Investments
750.09
Cash And Cash Equivalents
143.74
Other Short Term Investments
606.35
Receivables
0.00
Accounts Receivable
0.00
Other Receivables
—
Prepaid Assets
16.70
Other Current Assets
3.31
Total Non Current Assets
73.88
Net PPE
68.87
Gross PPE
92.45
Accumulated Depreciation
-23.58
Properties
0.00
Machinery Furniture Equipment
3.52
Construction In Progress
1.58
Other Properties
83.53
Leases
3.83
Goodwill And Other Intangible Assets
2.30
Other Non Current Assets
2.71
Total Liabilities Net Minority Interest
91.98
Current Liabilities
30.27
Payables And Accrued Expenses
23.40
Payables
9.21
Accounts Payable
9.21
Current Accrued Expenses
14.19
Pensionand Other Post Retirement Benefit Plans Current
0.70
Current Debt And Capital Lease Obligation
4.96
Current Capital Lease Obligation
4.96
Current Deferred Liabilities
0.00
Current Deferred Revenue
0.00
Other Current Liabilities
1.20
Total Non Current Liabilities Net Minority Interest
61.71
Long Term Debt And Capital Lease Obligation
48.50
Long Term Capital Lease Obligation
48.50
Other Non Current Liabilities
13.21
Stockholders Equity
752.00
Common Stock Equity
752.00
Capital Stock
0.13
Common Stock
0.13
Preferred Stock
0.00
Share Issued
127.46
Ordinary Shares Number
127.46
Treasury Shares Number
0.00
Additional Paid In Capital
2,152.65
Retained Earnings
-1,400.58
Gains Losses Not Affecting Retained Earnings
-0.20
Other Equity Adjustments
-0.20
Total Equity Gross Minority Interest
752.00
Total Capitalization
752.00
Working Capital
739.83
Invested Capital
752.00
Total Debt
53.47
Capital Lease Obligations
53.47
Net Tangible Assets
749.70
Tangible Book Value
749.70
Restricted Common Stock
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-235.46
+5.48%
-249.11
+17.05%
-300.32
-30.86%
-229.49
Cash Flow From Continuing Operating Activities
-235.46
+5.48%
-249.11
+17.05%
-300.32
-30.86%
-229.49
Net Income From Continuing Operations
-276.48
+18.13%
-337.71
+1.25%
-341.97
-17.72%
-290.51
Depreciation Amortization Depletion
3.56
-34.90%
5.46
+3.70%
5.27
+27.58%
4.13
Depreciation
3.56
-34.90%
5.46
+3.70%
5.27
+27.58%
4.13
Depreciation And Amortization
3.56
-34.90%
5.46
+3.70%
5.27
+27.58%
4.13
Other Non Cash Items
—
-13.21
-105.64%
-6.42
+45.00%
-11.68
Stock Based Compensation
62.42
-33.69%
94.14
+9.42%
86.03
+53.25%
56.14
Asset Impairment Charge
2.30
0.00
0.00
—
Operating Gains Losses
1.00
+1093.07%
-0.10
—
—
Gain Loss On Investment Securities
—
-0.10
—
—
Gain Loss On Sale Of PPE
1.00
0.00
0.00
—
Change In Working Capital
-23.31
-259.41%
14.62
+145.04%
-32.46
-388.62%
11.25
Change In Receivables
0.00
0.00
-100.00%
5.22
+1970.61%
-0.28
Changes In Account Receivables
0.00
0.00
-100.00%
0.31
+215.46%
0.10
Change In Prepaid Assets
1.61
+130.10%
-5.36
-15.23%
-4.65
-117.20%
-2.14
Change In Payables And Accrued Expense
-11.44
-211.41%
10.27
+207.07%
-9.59
-184.95%
11.29
Change In Accrued Expense
—
—
-32.14
-260.27%
20.06
Change In Payable
—
—
-2.39
-220.36%
1.99
Change In Account Payable
—
—
-2.39
-220.36%
1.99
Change In Other Working Capital
-11.95
-233.95%
8.92
+491.25%
1.51
+118.01%
-8.38
Change In Other Current Assets
—
—
0.00
0.00
Change In Other Current Liabilities
-1.53
-294.27%
0.79
+103.15%
-24.95
-331.94%
10.76
Investing Cash Flow
192.80
+569.29%
-41.08
-115.95%
257.63
+236.50%
-188.75
Cash Flow From Continuing Investing Activities
192.80
+569.29%
-41.08
-115.95%
257.63
+236.50%
-188.75
Net PPE Purchase And Sale
-0.41
+79.68%
-2.02
+51.09%
-4.13
+54.47%
-9.06
Purchase Of PPE
-0.41
+79.68%
-2.02
+51.09%
-4.13
+54.47%
-9.06
Sale Of PPE
—
—
—
—
Capital Expenditure
-0.41
+79.68%
-2.02
+51.09%
-4.13
+54.47%
-9.06
Net Investment Purchase And Sale
193.21
+594.58%
-39.06
-114.92%
261.76
+245.68%
-179.68
Purchase Of Investment
-122.97
+81.10%
-650.63
-68.76%
-385.54
+27.99%
-535.42
Sale Of Investment
316.18
-48.30%
611.56
-5.52%
647.30
+81.96%
355.74
Net Business Purchase And Sale
—
—
0.00
0.00
Purchase Of Business
—
—
0.00
0.00
Financing Cash Flow
1.60
-99.41%
270.15
+677.35%
34.75
-88.01%
289.91
Cash Flow From Continuing Financing Activities
1.60
-99.41%
270.15
+677.35%
34.75
-88.01%
289.91
Net Common Stock Issuance
0.00
-100.00%
265.89
+778.08%
30.28
-89.37%
284.74
Proceeds From Stock Option Exercised
1.60
-62.36%
4.26
-4.72%
4.47
-13.43%
5.17
Changes In Cash
-41.05
-104.88%
-20.04
-152.71%
-7.93
+93.82%
-128.32
Beginning Cash Position
126.41
-13.68%
146.44
-5.14%
154.37
-45.39%
282.70
End Cash Position
85.35
-32.48%
126.41
-13.68%
146.44
-5.14%
154.37
Free Cash Flow
-235.87
+6.08%
-251.12
+17.51%
-304.44
-27.62%
-238.55
Amortization Of Securities
-4.95
+59.81%
-12.31
-14.42%
-10.76
-1010.58%
1.18
Common Stock Issuance
0.00
-100.00%
265.89
+778.08%
30.28
-89.37%
284.74
Issuance Of Capital Stock
0.00
-100.00%
265.89
+778.08%
30.28
-89.37%
284.74
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category